Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Here, Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, outlines the importance of regulation when a novel therapy such as CAR T-cell therapy is introduced, and what to expect from the regulatory session taking place on Day 2 of the 2nd European CAR T-cell Meeting in Sitges, Spain.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.